Story perspectives

Targeting Key Enzymes Could Revolutionize Prostate Cancer Treatment

10/20/2025

38 9

Summary

Story summary

Researchers from Australia and China identified PDIA1 and PDIA5, enzymes that prolong prostate cancer by protecting cancer cells.
Targeting these enzymes could boost existing therapies, including enzalutamide, which is approved for prostate cancer.
A clinical trial involving over 1,000 men found that enzalutamide plus standard hormone therapy reduced death risk by over 40% in biochemically recurrent prostate cancer.
The study's implications could redefine guidelines and improve patient outcomes globally.

1 of 1

Story summary

Researchers from Australia and China identified PDIA1 and PDIA5, enzymes that prolong prostate cancer by protecting cancer cells.
Targeting these enzymes could boost existing therapies, including enzalutamide, which is approved for prostate cancer.
A clinical trial involving over 1,000 men found that enzalutamide plus standard hormone therapy reduced death risk by over 40% in biochemically recurrent prostate cancer.
The study's implications could redefine guidelines and improve patient outcomes globally.